|
 |
|
|||||||
|
|||||||||
DOI: 10.2337/dc06-9912
© 2006 by the American Diabetes Association
Reviews/Commentaries/ADA Statements |
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
1 Diabetes Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
2 University of North Carolina School of Medicine, Chapel Hill, North Carolina
3 Clinical Trials Unit, Charles R. Drew University, Los Angeles, California
4 Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands
5 Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University, Oxford, U.K.
6 Department of Internal Medicine and Endocrinology, Yale University School of Medicine, New Haven, Connecticut
7 Departments of Endocrinology and Metabolism, Mount Sinai Hospital, University of Toronto, Toronto, Canada
Address correspondence and reprint requests to David M. Nathan, MD, Diabetes Center, Massachusetts General Hospital, Boston, MA 02114. E-mail: dnathan@partners.org
Abbreviations: CVD, cardiovascular disease • DCCT, Diabetes Control and Complications Trial • GLP-1, glucagon-like peptide 1 • SMBG, self-monitoring of blood glucose • TZD, thiazolidinedione • UKPDS, U.K. Prospective Diabetes Study
| The first 300 words of the full text of this article appear below. |
 |
INTRODUCTION |
|---|
The epidemic of type 2 diabetes in the latter part of the 20th and in the early 21st century, and the recognition that achieving specific glycemic goals can substantially reduce morbidity, have made the effective treatment of hyperglycemia a top priority (1–3). While the management of hyperglycemia, the hallmark metabolic abnormality associated with type 2 diabetes, has historically had center stage in the treatment of diabetes, therapies directed at other coincident features, such as dyslipidemia, hypertension, hypercoagulability, obesity, and insulin resistance, have also been a major focus of research and therapy. Maintaining glycemic levels as close to the nondiabetic range as possible has been demonstrated to have a powerful beneficial impact on diabetes-specific complications, including retinopathy, nephropathy, and neuropathy in the setting of type 1 diabetes (4,5); in type 2 diabetes, more intensive treatment strategies have likewise been demonstrated to reduce complications (6–8). Intensive glycemic management resulting in lower HbA1c (A1C) levels has also been shown to have a beneficial effect on cardiovascular disease (CVD) complications in type 1 diabetes (9,10); however, the role of intensive diabetes therapy on CVD in type 2 diabetes remains under active investigation (11,12). Some therapies directed at lowering glucose levels have additional benefits with regard to CVD risk factors, while others lower glucose without additional benefits.
The development of new classes of blood glucose–lowering medications to supplement the older therapies, such as lifestyle-directed interventions, insulin, sulfonylureas, and metformin, has increased the treatment options for type 2 diabetes. Whether used alone or in combination with other blood glucose–lowering interventions, the availability of the newer agents has provided an increased number of choices for practitioners and patients and heightened uncertainty regarding the most appropriate means of
|
Process |
|---|
|
Glycemic goals of therapy |
|---|
|
Principles in selecting antihyperglycemic interventions |
|---|
Effectiveness in lowering glycemia.
Nonglycemic effects of medications.
|
Choosing specific diabetes interventions and their roles in treating type 2 diabetes |
|---|
Lifestyle interventions.
Medications.
Metformin.
Sulfonylureas.
Glinides.
-Glucosidase inhibitors.Thiazolidinediones.
Insulin.
Glucagon-like peptide 1 agonists (exenatide).
Amylin agonists (pramlintide).
|
How to initiate diabetes therapy and advance interventions |
|---|
|
Algorithm |
|---|
Step 1: lifestyle intervention and metformin.
Step 2: additional medications.
Step 3: further adjustments.
|
Rationale in selecting specific combinations |
|---|
|
Special considerations/patients |
|---|
|
Conclusions/summary |
|---|
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  V. R. Aroda and R. Ratner Approach to the Patient with Prediabetes J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3259 - 3265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Approaches to Treatment of Type 2 Diabetes Diabetes Care, August 1, 2008; 31(8): 1697 - 1703. [Full Text] [PDF]
|
|
|
|
|
|
A. D. Rao, N. Kuhadiya, K. Reynolds, and V. A. Fonseca Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies Diabetes Care, August 1, 2008; 31(8): 1672 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan, J. Kuenen, R. Borg, H. Zheng, D. Schoenfeld, R. J. Heine, and for the A1c-Derived Average Glucose (ADAG) Study G Translating the A1C Assay Into Estimated Average Glucose Values Diabetes Care, August 1, 2008; 31(8): 1473 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Rhee, D. C. Ziemer, J. Caudle, P. Kolm, and L. S. Phillips Use of a Uniform Treatment Algorithm Abolishes Racial Disparities in Glycemic Control The Diabetes Educator, July 1, 2008; 34(4): 655 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Almirall, M. Briculle, and J.-M. Gonzalez-Clemente Metformin-associated lactic acidosis in type 2 diabetes mellitus: incidence and presentation in common clinical practice Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2436 - 2438. [Full Text] [PDF]
|
|
|
|
|
|
E. Horton, W. T. Cefalu, S. T. Haines, and L. M. Siminerio Multidisciplinary Interventions: Mapping New Horizons in Diabetes Care The Diabetes Educator, July 1, 2008; 34(Supplement_4): 78S - 89S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Atkin and C. Walton Commentary: controversies in NICE guidance on management of type 2 diabetes BMJ, June 7, 2008; 336(7656): 1308 - 1309. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Y. Gandhi, M. H. Murad, A. Fujiyoshi, R. J. Mullan, D. N. Flynn, M. B. Elamin, B. A. Swiglo, W. L. Isley, G. H. Guyatt, and V. M. Montori Patient-Important Outcomes in Registered Diabetes Trials JAMA, June 4, 2008; 299(21): 2543 - 2549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F Dinneen and F. Waldron-Lynch Adjunctive prandial or biphasic insulin for type 2 diabetes improved glycaemic control but increased hypoglycaemia and weight gain Evid. Based Med., June 1, 2008; 13(3): 77 - 77. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Meece Effect of insulin pen devices on the management of diabetes mellitus Am. J. Health Syst. Pharm., June 1, 2008; 65(11): 1076 - 1082. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Larkin, V. A. Capasso, C.-L. Chen, E. K. Mahoney, B. Hazard, E. Cagliero, and D. M. Nathan Measuring Psychological Insulin Resistance: Barriers to Insulin Use The Diabetes Educator, May 1, 2008; 34(3): 511 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rizza, D. Eddy, and R. Kahn Cure, Care, and Commitment: What Can We Look Forward To? Diabetes Care, May 1, 2008; 31(5): 1051 - 1059. [Full Text] [PDF]
|
|
|
|
|
|
K. Esposito, M. Ciotola, D. Carleo, B. Schisano, L. Sardelli, D. Di Tommaso, L. Misso, F. Saccomanno, A. Ceriello, and D. Giugliano Post-Meal Glucose Peaks at Home Associate with Carotid Intima-Media Thickness in Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1345 - 1350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Q. Pham, A. Nogid, and R. Plakogiannis Sitagliptin: A novel agent for the management of type 2 diabetes mellitus Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 521 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. N. Pani, D. M. Nathan, and R. W. Grant Clinical Predictors of Disease Progression and Medication Initiation in Untreated Patients With Type 2 Diabetes and A1C Less Than 7% Diabetes Care, March 1, 2008; 31(3): 386 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ryan, M. B. E. Livingstone, P.-H. Ducluzeau, A. Salle, M. Genaitay, and P. Ritz Is a Failure to Recognize an Increase in Food Intake a Key to Understanding Insulin-Induced Weight Gain? Diabetes Care, March 1, 2008; 31(3): 448 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Massi-Benedetti and M. Orsini-Federici Treatment of Type 2 Diabetes With Combined Therapy: What are the pros and cons? Diabetes Care, February 1, 2008; 31(Supplement_2): S131 - S135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Standl and O. Schnell Insulin as a First-Line Therapy in Type 2 Diabetes: Should the use of sulfonylureas be halted? Diabetes Care, February 1, 2008; 31(Supplement_2): S136 - S139. [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Inzucchi and D. K. McGuire New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond Circulation, January 29, 2008; 117(4): 574 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Management of Type 2 Diabetes N. Engl. J. Med., January 17, 2008; 358(3): 293 - 297. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Fowler Diabetes Treatment, Part 3: Insulin and Incretins Clin. Diabetes, January 1, 2008; 26(1): 35 - 39. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, and B. Zinman Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, January 1, 2008; 31(1): 173 - 175. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Hoerger, J. E. Segel, E. W. Gregg, and J. B. Saaddine Is Glycemic Control Improving in U.S. Adults? Diabetes Care, January 1, 2008; 31(1): 81 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes--2008 Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54. [Full Text] [PDF]
|
|
|
|
|
|
P. S. Odegard and K. Capoccia Medication Taking and Diabetes: A Systematic Review of the Literature The Diabetes Educator, November 1, 2007; 33(6): 1014 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rosenstock and V. Fonseca Missing the Point: Substituting Exenatide for Nonoptimized Insulin: Going from bad to worse! Diabetes Care, November 1, 2007; 30(11): 2972 - 2973. [Full Text] [PDF]
|
|
|
|
|
|
G. T. McMahon and R. G. Dluhy Intention to Treat -- Initiating Insulin and the 4-T Study N. Engl. J. Med., October 25, 2007; 357(17): 1759 - 1761. [Full Text] [PDF]
|
|
|
|
|
|
R. R. Holman, K. I. Thorne, A. J. Farmer, M. J. Davies, J. F. Keenan, S. Paul, J. C. Levy, and the 4-T Study Group Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes N. Engl. J. Med., October 25, 2007; 357(17): 1716 - 1730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. B. Hirsch New Drugs for Diabetes: What Should the Regulatory Standards Be? DOC News, October 1, 2007; 4(10): 2 - 2. [Full Text]
|
|
|
|
|
|
M. J. Fowler Diabetes Treatment, Part 2: Oral Agents for Glycemic Management Clin. Diabetes, October 1, 2007; 25(4): 131 - 134. [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Odegard, S. M. Setter, and J. J. Neumiller Considerations for the Pharmacological Treatment of Diabetes in Older Adults Diabetes Spectr, October 1, 2007; 20(4): 239 - 247. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Exploring Treatment Strategies for Type 2 Diabetes Diabetes Care, October 1, 2007; 30(10): 2737 - 2745. [Full Text] [PDF]
|
|
|
|
 |
|
 I. W Campbell Metformin -- life begins at 50: A symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 2007 The British Journal of Diabetes & Vascular Disease, September 1, 2007; 7(5): 247 - 252. [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden The Avandia Debate Diabetes Care, September 1, 2007; 30(9): 2401 - 2408. [Full Text] [PDF]
|
|
|
|
|
|
C. Buell, D. Kermah, and M. B. Davidson Utility of A1C for Diabetes Screening in the 1999 2004 NHANES Population Diabetes Care, September 1, 2007; 30(9): 2233 - 2235. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Huizinga, C. L. Roumie, T. A. Elasy, H. J. Murff, R. Greevy, X. Liu, T. Speroff, and M. Griffin Changing Incident Diabetes Regimens: A Veterans Administration cohort study from 2000 to 2005 Diabetes Care, August 1, 2007; 30(8): e85 - e85. [Full Text] [PDF]
|
|
|
|
|
|
P. Hollander Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes Diabetes Spectr, July 1, 2007; 20(3): 159 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Haas Psychological Insulin Resistance: Scope of the Problem The Diabetes Educator, July 1, 2007; 33(Supplement_7): 228S - 231S. [Full Text] [PDF]
|
|
|
|
|
|
L. Blonde Easing the Transition to Insulin Therapy in People With Type 2 Diabetes The Diabetes Educator, July 1, 2007; 33(Supplement_7): 232S - 240S. [Full Text] [PDF]
|
|
|
|
|
|
R. W. Grant, D. J. Wexler, A. J. Watson, W. T. Lester, E. Cagliero, E. G. Campbell, and D. M. Nathan How Doctors Choose Medications to Treat Type 2 Diabetes: A national survey of specialists and academic generalists Diabetes Care, June 1, 2007; 30(6): 1448 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Kahn and B. Zinman Point: Recent Long-Term Clinical Studies Support an Enhanced Role for Thiazolidinediones in the Management of Type 2 Diabetes Diabetes Care, June 1, 2007; 30(6): 1672 - 1676. [Full Text] [PDF]
|
|
|
|
|
|
E. Al-Ozairi, L. Sibal, and P. Home Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): Good for Sulfonylureas? Diabetes Care, June 1, 2007; 30(6): 1677 - 1680. [Full Text] [PDF]
|
|
|
|
|
|
E. J. DeMaria Bariatric Surgery for Morbid Obesity N. Engl. J. Med., May 24, 2007; 356(21): 2176 - 2183. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden, S. E. Inzucchi, I. Irony, M. H. Parks, R. J. Meyer, M. L. Mintz, I. Raz, R. Eldor, and D. M. Nathan New Treatments for Diabetes N. Engl. J. Med., May 24, 2007; 356(21): 2219 - 2223. [Full Text] [PDF]
|
|
|
|
|
|
I. W Campbell and C. Day Sitagliptin -- enhancing incretin action The British Journal of Diabetes & Vascular Disease, May 1, 2007; 7(3): 134 - 139. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Westerbacka PROactive in Patients With Type 2 Diabetes and Previous Myocardial Infarction: Swinging the Sword of Damocles? J. Am. Coll. Cardiol., May 1, 2007; 49(17): 1781 - 1782. [Full Text] [PDF]
|
|
|
|
 |
|
 E. L Kleppinger and K. Helms The Role of Vildagliptin in the Management of Type 2 Diabetes Mellitus Ann. Pharmacother., May 1, 2007; 41(5): 824 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Malozowski Exenatide in Combination Therapy: Small Study, Big Market, and Many Unanswered Questions Ann Intern Med, April 3, 2007; 146(7): 527 - 528. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Goldstein Clinical Translation of "A Diabetes Outcome Progression Trial": ADOPT Appropriate Combination Oral Therapies in Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1226 - 1228. [Full Text] [PDF]
|
|
|
|
|
|
M. Pignone Initial Oral Therapy for Patients With Type 2 Diabetes Clin. Diabetes, April 1, 2007; 25(2): 64 - 65. [Full Text] [PDF]
|
|
|
|
|
|
P. S. Jellinger, H. E. Lebovitz, J. A. Davidson, and on behalf of the ACE/AACE Outpatient Glycemic Cont Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al. Diabetes Care, April 1, 2007; 30(4): e16 - e17. [Full Text] [PDF]
|
|
|
|